127 related articles for article (PubMed ID: 22495787)
1. The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781.
Bunge K; Macio I; Meyn L; Noguchi L; Parniak MA; Schwartz JL; Moncla B; Hillier S
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):337-43. PubMed ID: 22495787
[TBL] [Abstract][Full Text] [Related]
2. UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application.
Haaland RE; Evans-Strickfaden T; Holder A; Pau CP; McNicholl JM; Chaikummao S; Chonwattana W; Hart CE
Antimicrob Agents Chemother; 2012 Jul; 56(7):3592-6. PubMed ID: 22508307
[TBL] [Abstract][Full Text] [Related]
3. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men.
Ventuneac A; Carballo-Diéguez A; McGowan I; Dennis R; Adler A; Khanukhova E; Price C; Saunders T; Siboliban C; Anton P
AIDS Behav; 2010 Jun; 14(3):618-28. PubMed ID: 19757017
[TBL] [Abstract][Full Text] [Related]
4. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor.
Schwartz JL; Kovalevsky G; Lai JJ; Ballagh SA; McCormick T; Douville K; Mauck CK; Callahan MM
Sex Transm Dis; 2008 Apr; 35(4):414-9. PubMed ID: 18362865
[TBL] [Abstract][Full Text] [Related]
5. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.
Anton PA; Saunders T; Elliott J; Khanukhova E; Dennis R; Adler A; Cortina G; Tanner K; Boscardin J; Cumberland WG; Zhou Y; Ventuneac A; Carballo-Diéguez A; Rabe L; McCormick T; Gabelnick H; Mauck C; McGowan I
PLoS One; 2011; 6(9):e23243. PubMed ID: 21969851
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.
O'Loughlin J; Millwood IY; McDonald HM; Price CF; Kaldor JM; Paull JR
Sex Transm Dis; 2010 Feb; 37(2):100-4. PubMed ID: 19823111
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).
McGowan I; Gomez K; Bruder K; Febo I; Chen BA; Richardson BA; Husnik M; Livant E; Price C; Jacobson C;
AIDS; 2011 May; 25(8):1057-64. PubMed ID: 21505316
[TBL] [Abstract][Full Text] [Related]
8. Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781.
Yang H; Parniak MA; Isaacs CE; Hillier SL; Rohan LC
AAPS J; 2008 Dec; 10(4):606-13. PubMed ID: 19089644
[TBL] [Abstract][Full Text] [Related]
9. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.
Patton DL; Sweeney YT; Balkus JE; Rohan LC; Moncla BJ; Parniak MA; Hillier SL
Antimicrob Agents Chemother; 2007 May; 51(5):1608-15. PubMed ID: 17353240
[TBL] [Abstract][Full Text] [Related]
10. Design of tenofovir-UC781 combination microbicide vaginal gels.
Kiser PF; Mahalingam A; Fabian J; Smith E; Damian FR; Peters JJ; Katz DF; Elgendy H; Clark MR; Friend DR
J Pharm Sci; 2012 May; 101(5):1852-64. PubMed ID: 22359356
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled safety and acceptability trial of dextrin sulphate vaginal microbicide gel in sexually active women in Uganda.
Bakobaki JM; Lacey CJ; Bukenya MI; Nunn AJ; McCormack S; Byaruhanga RN; Okong P; Namukwaya SW; Grosskurth H; Whitworth JA
AIDS; 2005 Dec; 19(18):2149-56. PubMed ID: 16284465
[TBL] [Abstract][Full Text] [Related]
12. Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States.
Montgomery ET; Noguchi LM; Dai JY; Pan J; Biggio J; Hendrix C; Isaacs K; Watts DH; Schwartz JL; Piper J; Beigi R
AIDS Behav; 2018 Feb; 22(2):402-411. PubMed ID: 28550377
[TBL] [Abstract][Full Text] [Related]
13. Does tenofovir gel or do other microbicide products affect detection of biomarkers of semen exposure in vitro?
Snead MC; Kourtis AP; Melendez JH; Black CM; Mauck CK; Penman-Aguilar A; Chaney DM; Gallo MF; Jamieson DJ; Macaluso M; Doncel GF
Contraception; 2014 Aug; 90(2):136-41. PubMed ID: 24746557
[TBL] [Abstract][Full Text] [Related]
14. Lack of in vitro-in vivo correlation for a UC781-releasing vaginal ring in macaques.
McConville C; Smith JM; McCoy CF; Srinivasan P; Mitchell J; Holder A; Otten RA; Butera S; Doncel GF; Friend DR; Malcolm RK
Drug Deliv Transl Res; 2015 Feb; 5(1):27-37. PubMed ID: 25787337
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
[TBL] [Abstract][Full Text] [Related]
16. Acceptability of Carraguard vaginal microbicide gel among HIV-infected women in Chiang Rai, Thailand.
Whitehead SJ; McLean C; Chaikummao S; Braunstein S; Utaivoravit W; van de Wijgert JH; Mock PA; Siraprapasiri T; Friedland BA; Kilmarx PH; Markowitz LE
PLoS One; 2011; 6(9):e14831. PubMed ID: 21915249
[TBL] [Abstract][Full Text] [Related]
17. Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.
Richardson-Harman N; Mauck C; McGowan I; Anton P
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1422-33. PubMed ID: 22900504
[TBL] [Abstract][Full Text] [Related]
18. Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive.
Keller MJ; Carpenter CA; Lo Y; Einstein MH; Liu C; Fredricks DN; Herold BC
PLoS One; 2012; 7(10):e46901. PubMed ID: 23056520
[TBL] [Abstract][Full Text] [Related]
19. Acceptability of PRO2000 vaginal gel among HIV un-infected women in Pune, India.
Joglekar N; Joshi S; Kakde M; Fang G; Cianciola M; Reynolds S; Mehendale S;
AIDS Care; 2007 Jul; 19(6):817-21. PubMed ID: 17573603
[TBL] [Abstract][Full Text] [Related]
20. Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.
Cost M; Dezzutti CS; Clark MR; Friend DR; Akil A; Rohan LC
Antimicrob Agents Chemother; 2012 Jun; 56(6):3058-66. PubMed ID: 22430977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
